Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
PROPINE is an ophthalmic solution approved in 1980 for eye care indications. As a small-molecule eye drop, it delivers therapeutic benefit directly to ocular tissues. The specific mechanism of action and indication details are not currently documented in available data.
Asset is in advanced lifecycle stage with LOE approaching; commercial teams are likely in maintenance or transition mode with declining headcount investment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PROPINE currently shows zero linked job openings, reflecting its mature LOE-approaching lifecycle. Career opportunities on this asset are limited; roles focus on maintenance and lifecycle management rather than growth initiatives.
Worked on PROPINE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.